Skip to content

Investigate the Relationship Between Inflammatory and Coagulation in SAH CSF

Inhibition of Caspase-1 Reduces Pyroptotic Neuroinflammation and Tissue Factor-Induced Cerebrospinal Fluid Circulation Impairment After Subarachnoid Hemorrhage

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04938414
Enrollment
40
Registered
2021-06-24
Start date
2020-12-01
Completion date
2021-10-01
Last updated
2022-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subarachnoid Hemorrhage, Aneurysmal

Keywords

subarachnoid hemorrhage, coagulation, inflammation

Brief summary

Investigate the role of inflammasome and blood coagulation response in human cerebrospinal fluid after subarachnoid hemorrhage.

Detailed description

Investigate the role of inflammasome and blood coagulation response in human cerebrospinal fluid after subarachnoid hemorrhage (SAH). 1.40 patients with SAH will be included. The CSF will used for ELISA test for inflammatory factors and cogulation factors. 2.CSF obtained from 4 patients with non-neuroloogical disease with 4 addittional SAH patients will be used for Mass Spectrometry

Interventions

DIAGNOSTIC_TESTLumbar puncture

Lumbar puncture to obtain the cerebrospinal fluid and for diagnostic test

Sponsors

Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
30 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* SAH patients with modified Fisher Scale 3-4.

Exclusion criteria

* Patients with history of CNS disease (e.g., stroke, traumatic brain injury, CNS infection) or accompanied by serious comorbidities before SAH onset (e.g., severe coagulation disorders, malignant tumor, uncontrollable heart disease, and hypertension) or other organ dysfunctions within 6 months were excluded from the study

Design outcomes

Primary

MeasureTime frameDescription
Length of hospital stayevaluated 1day after dischargeLength of hospital stay
modified Rankin Scaleevaluated 1day after dischargemodified Rankin Scale (mRS) at discharge. mRS ranging from 0-5, higher represents worse
Glasgow Outcome Scaleevaluated 1day after dischargeGlasgow Outcome Scale (GOS) at discharge, GOS ranging from 0-5, higher represents better

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026